🔎 Trials Near Me

Início › Câncer de Mama › Texas

Ensaios clínicos de Câncer de Mama em Texas

178 estudos para Câncer de Mama estão buscando participantes em locais em Texas.

Cidades em Texas

Texto oficial do estudo (Inglês)

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

  • New Experimental Therapeutics - NEXT Oncology, Austin
  • Texas Oncology, Bedford
  • UT Southwest Simmons Cancer Center, Dallas
  • e mais 2
RecrutandoFase 1/2
Idades 12 e acima · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT04585750

Phase IIIb Study of Ribociclib + ET in Early Breast Cancer

  • El Paso Texas Oncology, El Paso
  • Kelsey Seybold Clinic, Houston
  • University of Texas, Houston
  • e mais 2
RecrutandoFase 3
Idades de 18 a 100 · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT05827081

A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer

  • Research Site, Houston
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT07205822

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

  • The Don and Sybil Harrington Cancer Center, Amarillo
  • UT MD Anderson Cancer Center, Houston
  • Audie L Murphy VA Hospital, San Antonio
RecrutandoEstudo observacionalVoluntários saudáveis bem-vindos
Idades de 40 a 75 · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT05334069

Prediction Of Lymphedema In Patients With Inflammatory BreastCancer Using Preoperative Bioimpedance Measurements

  • UT MD Anderson Cancer Center, Houston
RecrutandoEstudo observacional
Idades 18 e acima · Mulheres · Atualizado em 2 de out. de 2026 · NCT07855627

A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

  • The University of Texas MD Anderson Cancer Center - Texas Medical Center, Houston
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT06760819

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

  • The University of Texas MD Anderson Cancer Center, Houston
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 1 de out. de 2026 · NCT06172478

A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer

  • University of Texas Southwestern, Dallas
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 1 de out. de 2026 · NCT07701941

A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer

  • Texas Oncology DFW, Dallas
  • The University of Texas Southwestern Medical Center, Dallas
  • Texas Oncology Gulf Coast, Houston
  • e mais 1
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 1 de out. de 2026 · NCT07102381

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

  • SCRI at Mary Crowley, Dallas
  • University of Texas Southwestern Medical Center, Dallas
  • The University of Texas MD Anderson Cancer Center, Houston
  • e mais 1
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 1 de out. de 2026 · NCT06625775

A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer

  • Texas Oncology, Dallas
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 1 de out. de 2026 · NCT06369285

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

  • The Methodist Hospital Research Institute, Houston
  • The University of Texas MD Anderson Cancer Center, Houston
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 30 de set. de 2026 · NCT06324357

Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors

  • NEXT Houston, Galveston
  • NEXT Oncology - PARENT, San Antonio
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 29 de set. de 2026 · NCT07360314

A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

  • Research Site, Houston
  • Research Site, Round Rock
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 29 de set. de 2026 · NCT05877599

A Phase 1 Study of IM-1617 in Participants With Advanced Cancer

  • NEXT Dallas, Irving
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 29 de set. de 2026 · NCT07578571

BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors

  • The University of Texas Md Anderson Cancer Center, Houston
  • Next Oncology Dallas, Irving
  • Next Oncology, San Antonio
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 28 de set. de 2026 · NCT06120283

IKS014 in Advanced Solid Tumors That Express HER2

  • START Dallas - Fort Worth, Fort Worth
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 28 de set. de 2026 · NCT05872295

Study of AVZO-021 in Patients With Advanced Solid Tumors

  • Avenzo Therapeutics Recruiting Site, Dallas
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 28 de set. de 2026 · NCT05867251

A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

  • Texas Oncology - DFW ( Site 8003), Dallas
  • JPS Health Network ( Site 0067), Fort Worth
  • Texas Oncology - Gulf Coast ( Site 8006), Houston
  • e mais 3
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 28 de set. de 2026 · NCT07060807

An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors

  • Next Oncology Austin, Austin
  • The University of Texas Md Anderson Cancer Center, Houston
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 28 de set. de 2026 · NCT07222267

Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy

  • M D Anderson Cancer Center, Houston
Recrutando
Idades 30 e acima · Mulheres · Atualizado em 25 de set. de 2026 · NCT02945579

Opioid-Sparing Effects of Nurse-Delivered Hypnosis During Breast Cancer Surgery

  • M D Anderson Cancer Center, Houston
RecrutandoFase 2/3
Idades 18 e acima · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT05766891

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

  • Hendrick Medical Center ( Site 0009), Abilene
  • Texas Oncology - DFW ( Site 8009), Dallas
  • UT Southwestern ( Site 0092), Dallas
  • e mais 7
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT06966700

A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

  • Texas Oncology-Dallas Presbyterian Hospital ( Site 8000), Dallas
  • Parkland Health and Hospital System ( Site 0069), Dallas
  • UT Southwestern Medical Center ( Site 0050), Dallas
  • e mais 3
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT06312176

Group-based Comprehensive Lifestyle Program for Women With Metastatic Breast Cancer

  • The University of Texas M. D. Anderson Cancer Center, Houston
Recrutando
Idades 18 e acima · Mulheres · Atualizado em 25 de set. de 2026 · NCT07179809

ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer

  • University of Texas Southwestern Medical Center, Dallas
  • Houston Methodist Cancer Center, Houston
  • The University of Texas M.D. Anderson Cancer Center, Houston
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT07007559

TRAIL-R2 and HER2 Bi-Specific Chimeric Antigen Receptor (CAR) T Cells for the Treatment of Metastatic Breast Cancer

  • Houston Methodist Hospital, Houston
RecrutandoFase 1
Idades de 18 a 80 · Todos os sexos · Atualizado em 24 de set. de 2026 · NCT06251544

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors

  • NEXT Oncology - Irving, Irving
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 23 de set. de 2026 · NCT06618287

Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

  • Clinical Trial Site, Dallas
  • Clinical Trial Site, Dallas
  • Clinical Trial Site, Denton
  • e mais 3
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 23 de set. de 2026 · NCT07085767

Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer

  • Houston Methodist Hospital, Houston
Recrutando
Idades 18 e acima · Todos os sexos · Atualizado em 23 de set. de 2026 · NCT07214532

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

  • Hendrick Medical Center, Abilene
  • World Research Link, Baytown
  • Parkland Health and Hospital System, Dallas
  • e mais 10
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 22 de set. de 2026 · NCT07174336

ARTIDIS Nanomechanical Generated Measurements for Early Breast Lesions

  • University of Texas Southwestern Medical Center, Dallas
  • Baylor College of Medicine, Houston
  • MD Anderson Cancer Clinic - Mays Clinic, Houston
Recrutando
Idades 18 e acima · Todos os sexos · Atualizado em 22 de set. de 2026 · NCT06085833

A Study of LY4257496 in Participants With Cancer (OMNIRAY)

  • Texas Oncology - DFW (Sammons CC), Dallas
  • MD Anderson Cancer Center, Houston
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 22 de set. de 2026 · NCT07114601

A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer

  • University of Texas MD Anderson Cancer Center, Houston
  • Houston Methodist Hospital, Houston
  • Oncology Consultants P.A., Houston
  • e mais 1
RecrutandoFase 2
Idades 18 e acima · Mulheres · Atualizado em 22 de set. de 2026 · NCT07287098

A Study of LY4337713 in Participants With FAP-Positive Solid Tumors

  • Texas Oncology - DFW (Sammons CC), Dallas
  • Baylor College of Medicine, Houston
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 22 de set. de 2026 · NCT07213791

A Study of JNJ-101684362 (HLD-0117) in Patients With Metastatic Breast Cancer

  • South Texas Accelerated Research Therapeutics, LLC (START), San Antonio
RecrutandoFase 1
Idades 18 e acima · Mulheres · Atualizado em 21 de set. de 2026 · NCT07524855

A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer

  • Renovatio Clinical - El Paso, El Paso
  • JPS Health Network, Fort Worth
  • Renovatio Clinical, The Woodlands
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 21 de set. de 2026 · NCT05894239

Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies

  • Baylor College of Medicine, Houston
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 18 de set. de 2026 · NCT07340541

Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients

  • M D Anderson Cancer Center, Houston
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 18 de set. de 2026 · NCT04038619

Fonte: ClinicalTrials.gov, dados obtidos em 5 de out. de 2026. Cada estudo define seus próprios critérios de elegibilidade; a equipe do estudo decide quem pode participar.